Pharynx and esophagus: PET/CT

Jonathan E. McConathy, Farrokh Dehdashti

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

Abstract

This chapter reviews important considerations for the performance and interpretation of [18F]fluorodeoxyglucose (FDG)-PET/CT in the diagnostic evaluation of patients with esophageal cancer. Accurate staging is the primary basis for selecting appropriate treatment for patients with esophageal cancer. Attention to patient preparation, imaging protocols, potential artifacts and diagnostic pitfalls are critical for performing high quality FDG-PET/CT studies. The most established role of FDG-PET/CT in esophageal cancer is for staging of disease, particularly for the detection of distant metastatic disease. There is also evidence that FDG-PET/CT can be used to evaluate response to neoadjuvant therapy, although the impact on patient outcomes is not yet well-established.

Original languageEnglish
Title of host publicationAbdominal Imaging
PublisherSpringer-Verlag Berlin Heidelberg
Pages27-44
Number of pages18
Volume9783642133275
ISBN (Electronic)9783642133275
ISBN (Print)3642133266, 9783642133268
DOIs
StatePublished - Nov 1 2013

Fingerprint

Dive into the research topics of 'Pharynx and esophagus: PET/CT'. Together they form a unique fingerprint.

Cite this